← ANALYST RATINGS · TIPRANKS
Context Therapeutics (CNTX): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy1 Hold0 Sell
Ratings of 6 analysts in the last 3 months12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $3.20, the highest $5.00, the lowest $2.00. The average is +1,211.5% from the last price of $0.24.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $0.24 → $0.23−4.1% | Hold | −4.9% | Upgrade | 16.10.26on TipRanks 02:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $0.24 → $0.23−4.6% | Sell | −7.0% | Reiterated | 16.10.26on TipRanks 02:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $0.25 → $0.23−7.3% | Hold | −6.1% | Reiterated | 16.10.26on TipRanks 02:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.24 → $0.22−11.0% | Sell | −10.7% | Downgrade | 16.10.26on TipRanks 02:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $0.24 → $0.23−6.2% | Sell | −7.4% | Reiterated | 16.10.26on TipRanks 02:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.25 → $0.23−7.7% | Sell | −6.6% | Downgrade | 16.10.26on TipRanks 02:05 | — | |
| Jason McCarthy★★★★★★★★★★#12398 · hits 30% · avg −13.6% | Maxim Group | $4.00 | Buy | +1,539.3% | Reiterated | 10.08.26on TipRanks Aug 11 15:55 | −6.6%next day +3.2% · 5 days +17.3% | ↗ |
| Charles Zhu★★★★★★★★★★#351 · hits 64% · avg +25.8% | LifeSci Capital | $2.00 | Hold | +719.7% | Downgrade | 08.08.26on TipRanks Aug 6 16:37 | −4.6%next day −6.6% · 5 days +7.5% | ↗ |
| Silvan Turkcan★★★★★★★★★★#10721 · hits 17% · avg −13.5% | Citizens JMP | $4.00 → $3.00−25.0% | Buy | +1,129.5% | Reiterated | 06.08.26on TipRanks 15:30 | −27.1%next day −4.6% · 5 days −0.8% | ↗ |
| Matt Phipps★★★★★★★★★★#2652 · hits 48% · avg +4.8% | William Blair | — | Buy | — | Reiterated | 06.08.26on TipRanks 09:15 | −27.1%next day −4.6% · 5 days −0.8% | ↗ |
| Boris Peaker★★★★★★★★★★#357 · hits 49% · avg +22.6% | JonesTrading | $7.00 → $2.00−71.4% | Buy | +719.7% | Reiterated | 06.08.26on TipRanks 08:50 | −27.1%next day −4.6% · 5 days −0.8% | ↗ |
| Emily Bodnar★★★★★★★★★★#2140 · hits 39% · avg +7.2% | H.C. Wainwright | $5.00 | Buy | +1,949.2% | Reiterated | 06.08.26on TipRanks 06:25 | −27.1%next day −4.6% · 5 days −0.8% | ↗ |
| Biren Amin★★★★★★★★★★#1671 · hits 46% · avg +7.6% | Piper Sandler | $7.00 | Buy | +2,768.9% | Reiterated | 02.06.26on TipRanks 07:15 | −13.4%next day −14.6% · 5 days −34.2% | ↗ |
| Paul Jeng★★★★★★★★★★#9457 · hits 52% · avg −1.9% | Guggenheim | $5.00 | Buy | +1,949.2% | Reiterated | 06.05.26on TipRanks May 7 07:00 | −2.6%next day −3.0% · 5 days −3.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Context Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $3.20 at a price of $0.30 (+966.7%); now: $3.20 at $0.24 (+1,211.5%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 18 | 20 | 15 | 10 | 4 | 4 |
| Buy | 4 | 4 | 3 | 2 | 1 | 1 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.11 (from $-0.16 to $-0.07). Last quarter: $-0.15.
Best top-analyst consensus in the sector · Healthcare
About Context Therapeutics
- CEO: Martin A. Lehr
- Employees: 15
- 2001 Market Street, Philadelphia, PA, 19103, US
- www.contexttherapeutics.com
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Data from the stock’s TipRanks forecast page, read 142 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗